Jade Biosciences, Inc. (JBIO)
| Market Cap | 1.31B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -95.10M |
| Shares Out | 59.36M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,664,341 |
| Open | 21.80 |
| Previous Close | 21.81 |
| Day's Range | 21.16 - 22.50 |
| 52-Week Range | 6.67 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 48.50 (+120.46%) |
| Earnings Date | Aug 12, 2026 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 120.46% from the latest price.
News
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences initiated with a Buy at UBS
UBS initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $45 price target The firm believes the company’s lead program JADE101 could be a best-in-class drug in the…
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences Proxy statement: Proxy filing
Jade Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Jade Biosciences 10M share Secondary priced at $15.00
Jefferies, TD Cowen and UBS acted as joint book running managers for the offering.
Jade Biosciences Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences announces common stock offering, no amount given
Jade Biosciences (JBIO) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain…
Jade Biosciences Announces Proposed Underwritten Public Offering
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences price target raised to $47 from $32 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Jade Biosciences (JBIO) to $47 from $32 and keeps a Buy rating on the shares. Following the release of detailed…
Jefferies says Jade Biosciences JADE101 data came in line with bull case
Jefferies noted that Jade Biosciences (JBIO)’ interim JADE101 trial data hit the firm’s bull case expectations. The firm added that management sees once every 12 weeks dosing with a single…
Jade Biosciences announces interim results from JADE101 trial
Jade Biosciences (JBIO) announced interim results from its Phase 1 trial evaluating JADE101, an investigational anti-A Proliferation-Inducing Ligand, or APRIL, monoclonal antibody in development for t...
Jade Biosciences Transcript: Study update
JADE101 phase I results in healthy volunteers showed rapid, deep, and sustained IgA reductions (~70%), favorable safety, and support for a 12-week dosing interval. Modeling and biomarker data predict best-in-class efficacy for IgAN, with phase II and III trials underway and a strong focus on convenience and market differentiation.
Jade Biosciences Slides: Study update
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Jade Biosciences Press release: Study update
Jade Biosciences issued a press release on June 1, 2026, disclosing material business information to investors.
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences Slides: Company presentation
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on devel...
Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial
Jade Biosciences (JBIO) announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal...
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences announces first participant dosed in Phase 2 Juniper trial
Jade Biosciences (JBIO) announced that the first participant has been dosed in Juniper, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy. JADE101 is des...
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on devel...
Jade Biosciences price target raised to $34 from $24 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Jade Biosciences (JBIO) to $34 from $24 and keeps an Outperform rating on the shares. Preliminary Phase 1 JADE101 data…
Jade Biosciences price target raised to $32 from $23 at Guggenheim
Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $32 from $23 and keeps a Buy rating on the shares. Following the Q1 update, the firm is revising…
Jade Biosciences files $600M mixed securities shelf
17:17 EDT Jade Biosciences (JBIO) files $600M mixed securities shelf
Jade Biosciences files to sell 39.54M shares of common stock for holders
17:22 EDT Jade Biosciences (JBIO) files to sell 39.54M shares of common stock for holders